All terms
5-Day Report
Expedited FDA MDR for events requiring remedial action to prevent unreasonable risk of substantial harm.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed September 19, 2026
Definition
21 CFR 803.53 requires a 5-Day Report when a manufacturer becomes aware that a reportable event necessitates remedial action to prevent unreasonable risk. Filed in addition to standard 30-day MDRs as applicable. A 5-day report is also required when FDA requests one in writing. The clock starts when any employee who is a person with management or supervisory responsibilities becomes aware of the event. Remedial action can include a recall, correction or design change; if the action is not taken to prevent an unreasonable risk to public health, a 30-day report may still apply. Reports are submitted through eMDR. What the regulation says
The FDA, under 21 CFR 803.53, mandates a 5-Day Report when a manufacturer determines that a reportable event requires prompt remedial action to prevent an unreasonable risk of substantial harm to the public health. This report supplements the standard 30-day Medical Device Reporting (MDR) requirements outlined in 21 CFR Part 803. Regulators expect manufacturers to have robust processes for identifying events that meet the criteria for expedited reporting.What this means in practice
Triggers tend to be safety-relevant trends or single severe events; misreading the threshold is a common 483 finding.Examples
- A manufacturer discovers a critical software bug in an implanted cardiac device that could lead to sudden device failure, prompting immediate communication with users and a software update, requiring a 5-Day Report.
- Following several complaints of severe patient injury linked to a specific design flaw in a surgical instrument, the manufacturer initiates a voluntary recall, triggering the need for a 5-Day Report.
- A MedTech company becomes aware of a cybersecurity vulnerability in their network-connected infusion pump that allows unauthorized remote access, leading to an immediate patch release and a 5-Day Report.
Common pitfalls
- •Misinterpreting the "unreasonable risk of substantial harm" threshold is a common compliance pitfall, leading to underreporting.
- •Failing to initiate a 5-Day Report concurrently with determining the need for remedial action can result in a late submission.
- •Assuming a 30-day MDR is always sufficient without evaluating the need for expedited reporting is a frequent mistake.
- •Inadequate documentation of the decision-making process for filing or not filing a 5-Day Report can lead to regulatory scrutiny.
- •Not clearly defining "remedial action" within internal procedures can cause confusion and reporting delays.
Frequently asked questions
A 5-Day Report is specifically required when a manufacturer identifies a reportable event necessitating immediate remedial action to prevent an unreasonable risk of substantial harm, whereas a 30-Day MDR covers most other reportable adverse events.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMore in Post-Market
· Same categoryPost-Market
Annual Report (PMA)
Yearly report required for Class III PMA devices summarizing changes, complaints, and post-approval study status.
Post-Market
Customer Notification Letter
Communication to users notifying them of a safety issue, corrective action, or important product information.
Post-Market
Electronic Medical Device Reporting(eMDR)
FDA's mandatory electronic submission system for Medical Device Reports.
Post-Market
FDA Recall Classifications I, II, III
FDA's risk-based grading of recalls based on potential for harm.
Cited by
Where this term appears across MedTech Terms.
Latest in MedTech
Sources
3 sourcesSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
Tier 1Binding law and standards· 1Tier 2Regulator guidance and consensus· 2
Link health: 3 verified· last checked 2026-06-20
eCFR·1FDA·2
- 121 CFR 803Tier 1 VerifiedeCFRecfr.gov
- 2FDA MAUDE DatabaseTier 2 VerifiedFDAaccessdata.fda.gov
- 3FDA Recalls - Medical DevicesTier 2 VerifiedFDAfda.gov
Inline markers like [1] jump to the matching reference above.